| Previous Close | 2.19 |
| Volume | 99,850 |
| Price / Book | 1.32 |
| 52 Weeks Range |
| Profit Margin | -215.24% |
| Operating Margin (TTM) | -242.68% |
| Diluted EPS (TTM) | -0.220 |
| Quarterly Revenue Growth (YOY) | 18.30% |
| Total Debt/Equity (MRQ) | 16.10% |
| Current Ratio (MRQ) | 3.80 |
| Operating Cash Flow (TTM) | -29.08 M |
| Levered Free Cash Flow (TTM) | -7.41 M |
| Return on Assets (TTM) | -49.03% |
| Return on Equity (TTM) | -93.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Veru Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.24 |
Select this tab to load the latest available analysis.
|
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.19% |
| % Held by Institutions | 33.43% |
No data within this time range.
No data within this time range.
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 28 Apr 2014 | 24 Mar 2014 | 07 May 2014 | 0.07 Cash |
| 27 Jan 2014 | 16 Dec 2013 | 05 Feb 2014 | 0.07 Cash |
| 28 Oct 2013 | 03 Oct 2013 | 06 Nov 2013 | 0.07 Cash |
| 29 Jul 2013 | 15 Jul 2013 | 07 Aug 2013 | 0.07 Cash |
| 28 Jan 2013 | 03 Jan 2013 | 06 Feb 2013 | 0.06 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2014 | 0.140 | 2 | 0.36 |
| 2013 | 0.200 | 3 | 0.24 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |